MTNB

Business Context and Reporting Period

Company: Matinas Biopharma Holdings, Inc. (MTNB)
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: September 30, 2025
Business Overview: A clinical-stage biopharmaceutical company focused on its lipid nanocrystal (LNC) platform, specifically advancing the lead product candidate MAT2203. The company is currently pausing development activities to conserve cash and seeking strategic partnerships or licensing deals to fund Phase 3 trials.

Key Financial Metrics

Liquidity: As of September 30, 2025, the company held $5.435 million in cash and cash equivalents and $250,000 in restricted cash. Management states these funds are insufficient to fund operations beyond the next twelve months.

Material Changes vs. Prior Period

• Expense Reduction: Total operating expenses decreased significantly year-over-year. For the nine months ended September 30, 2025, expenses were $5.36 million compared to $16.12 million in the prior year.
  • R&D Expenses: Dropped from $9.057 million (YTD 2024) to $85k (YTD 2025) due to the pause in the MAT2203 development program and headcount reductions.
  • G&A Expenses: Decreased from $7.067 million (YTD 2024) to $5.275 million (YTD 2025) driven by lower stock-based compensation and reduced headcount.
• Warrant Liability Reclassification: In June 2025, warrant terms were amended, allowing reclassification from liability to equity. This eliminated the recurring fair value adjustments that previously impacted the income statement, though a $3.161 million loss was recognized in YTD 2025 prior to reclassification.
• Capital Structure Changes:
  • Issued 3,300 shares of Series C Convertible Preferred Stock in a private placement, raising $3.3 million gross proceeds.
  • Exchanged 466,666 warrants for common stock, resulting in a $618k deemed dividend.
  • Increased authorized common stock from 250 million to 500 million shares.
• Asset Sales: Sold unused laboratory equipment for $320k, recognizing a $110k gain.

Outlook, Risks, and Management Commentary

• Going Concern Warning: The filing explicitly states that substantial doubt exists regarding the company's ability to continue as a going concern. Cash on hand is not sufficient to fund operations beyond 12 months.
• Strategic Focus: Management is prioritizing the monetization of MAT2203 through licensing or sale to a partner to secure funding for Phase 3 trials. They are also evaluating other strategic options, including mergers or in-licensing assets.
• Financing Needs: Future funding will likely come from equity offerings, debt financing, or strategic collaborations. The company has an At-The-Market (ATM) sales agreement with $44.191 million remaining capacity but has not utilized it in the current period.
• Internal Controls: The company disclosed a material weakness in internal control over financial reporting related to the processing of non-routine transactions (specifically indefinite-lived asset impairment assessments). Remediation is underway but not yet complete.

Investor Verification Checklist

• Cash Runway: Verify the specific timeline for cash depletion and the status of any ongoing fundraising efforts or partnership negotiations.
• Preferred Stock Terms: Review the liquidation preferences and conversion terms of the 3,155 outstanding Series C Preferred shares.
• Warrant Dilution: Assess the dilution impact of the 11.36 million outstanding warrants and the 5.38 million shares underlying the convertible preferred stock.
• Internal Control Remediation: Monitor progress on fixing the material weakness in internal controls to ensure future financial reporting reliability.
• Asset Sale Completion: Confirm the sale of the remaining $70k of equipment held for sale.